X4 Pharmaceuticals, Inc. (XFOR)
3.73
-0.12
(-3.12%)
USD |
NASDAQ |
Jun 10, 16:00
3.72
-0.01
(-0.27%)
After-Hours: 20:00
X4 Pharmaceuticals Enterprise Value : 195.35M for June 10, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 10, 2026 | 195.35M |
| June 09, 2026 | 206.66M |
| June 08, 2026 | 193.46M |
| June 05, 2026 | 204.78M |
| June 04, 2026 | 221.76M |
| June 03, 2026 | 217.98M |
| June 02, 2026 | 224.58M |
| June 01, 2026 | 231.19M |
| May 29, 2026 | 250.05M |
| May 28, 2026 | 234.02M |
| May 27, 2026 | 223.64M |
| May 26, 2026 | 220.81M |
| May 22, 2026 | 224.58M |
| May 21, 2026 | 224.58M |
| May 20, 2026 | 199.12M |
| May 19, 2026 | 186.86M |
| May 18, 2026 | 190.63M |
| May 15, 2026 | 215.15M |
| May 14, 2026 | 220.81M |
| May 13, 2026 | 242.51M |
| May 12, 2026 | 252.88M |
| May 11, 2026 | 267.97M |
| May 08, 2026 | 261.37M |
| May 07, 2026 | 248.16M |
| May 06, 2026 | 256.65M |
| Date | Value |
|---|---|
| May 05, 2026 | 239.68M |
| May 04, 2026 | 240.62M |
| May 01, 2026 | 238.73M |
| April 30, 2026 | 227.41M |
| April 29, 2026 | 230.24M |
| April 28, 2026 | 232.13M |
| April 27, 2026 | 240.62M |
| April 24, 2026 | 231.19M |
| April 23, 2026 | 247.22M |
| April 22, 2026 | 260.43M |
| April 21, 2026 | 236.85M |
| April 20, 2026 | 238.73M |
| April 17, 2026 | 248.16M |
| April 16, 2026 | 234.02M |
| April 15, 2026 | 251.94M |
| April 14, 2026 | 239.68M |
| April 13, 2026 | 233.07M |
| April 10, 2026 | 230.24M |
| April 09, 2026 | 227.41M |
| April 08, 2026 | 225.53M |
| April 07, 2026 | 195.35M |
| April 06, 2026 | 227.41M |
| April 02, 2026 | 243.45M |
| April 01, 2026 | 253.82M |
| March 31, 2026 | 233.07M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Kyverna Therapeutics, Inc. | 260.99M |
| Arrowhead Pharmaceuticals, Inc. | 9.517B |
| Oncolytics Biotech, Inc. | 87.93M |
| Sangamo Therapeutics, Inc. | 53.47M |
| Sarepta Therapeutics, Inc. | 1.979B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -20.24M |
| Revenue (Quarterly) | 2.708M |
| Total Expenses (Quarterly) | 22.95M |
| EPS Diluted (Quarterly) | -0.1603 |
| Gross Profit Margin (Quarterly) | 76.59% |
| Profit Margin (Quarterly) | -747.5% |
| Earnings Yield | -121.7% |
| Normalized Earnings Yield | -128.07 |